drugset
drugset / Trial / NCT07515027

Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery

NCT07515027 ↗

Recruiting 204 enrolled Shanghai Chest Hospital
RandomizedParallel-groupDouble-blindPrevention

Summary

This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.

Timeline

Start
2026-04-07
Primary completion
2026-11-01
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Background dolasetron Small molecule 12.5 mg —

Indications

No indication recorded.